Corifollitropin alfa versus daily recombinant FSH for ovarian stimulation in women of advanced maternal age: a cost-minimization analysis in an out-of-pocket setting
G. N. Cecchino, B. R. Carvalho, Y. Ramires, R. L. P. Bueno, L. A. Lucio, V. P. Santana · 2026
Read Corifollitropin alfa versus daily recombinant FSH for ovarian stimulation in women of advanced maternal age: a cost-minimization analysis in an out-of-pocket setting by G. N. Cecchino, B. R. Carvalho, Y. Ramires, R. L. P. Bueno, L. A. Lucio, V. P. Santana (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13624120.txt.
Description
Cecchino and five co-authors compared the costs of two fertility drug plans in a 2026 analysis. In Brazil, most fertility care is paid out of pocket, and one cycle can cost more than a month's income. The study focused on women of advanced maternal age, from 35 to 42, who need drugs to stimulate their ovaries.
One plan uses a single long-acting injection, corifollitropin alfa. The other uses daily shots of recombinant FSH. Assuming both work equally well, the authors compared drug prices from the official Brazilian database. The single-injection plan cut costs in every scenario tested. For patients paying themselves, such savings can decide whether treatment starts at all.
Catalog record
| CREATOR | G. N. Cecchino, B. R. Carvalho, Y. Ramires, R. L. P. Bueno, L. A. Lucio, V. P. Santana |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 21 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |